Los Angeles – Jay M. Moyes, a director at Puma Biotechnology, Inc. (NASDAQ:PBYI), disposed of 22,000 shares of common stock for a total value of $158,796 on June 12, 2026. The shares were sold at prices ranging from $6.98 to $7.32, with a weighted average price of $7.218 per share. This transaction was executed under a pre-arranged 10b5-1(c) trading plan adopted on March 12, 2025.
The sale comes as Puma Biotechnology shares have surged ~105% over the past year, currently trading at $7.09. According to InvestingPro analysis, the stock remains undervalued relative to its Fair Value, suggesting potential upside ahead. The company maintains a P/E ratio of 14.74 and earned $0.48 per share over the last twelve months.
The sale followed an acquisition by Mr. Moyes of 27,000 shares of common stock on June 11, 2026. These shares were granted as Restricted Stock Units (RSUs) at a price of $0 per share. The RSUs are set to vest in full on the earlier of the one-year anniversary of the grant date or the date of the annual shareholder meeting following the grant date, contingent on Mr. Moyes’ continued service with the company.
Following these transactions, Mr. Moyes directly holds 58,322 shares of Puma Biotechnology common stock.
In other recent news, Puma Biotechnology Inc. reported its first-quarter 2026 earnings, which did not meet analyst expectations. The company recorded a net loss per share of -$0.04, falling short of the forecasted $0.00. Additionally, revenue for the quarter was $44.8 million, which was below the anticipated $49 million, marking a revenue shortfall of 8.57%. These results highlight a challenging quarter for Puma Biotech, as the earnings and revenue figures were lower than expected. The company’s financial performance has attracted attention from investors and analysts alike. No recent upgrades or downgrades from analyst firms were mentioned in the reports. These developments are crucial for investors looking to understand the current state of Puma Biotech.